BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
Introduction 
The  applicant  Ligand  Pharmaceuticals  UK  Ltd  submitted  on  24  November  1999  an  application  for 
Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) 
for Targretin, through the centralised procedure. After agreement by the CPMP on 29 July 1999, this 
medicinal  product  is  referred  to  Part  B  of  the  Annex  to  Council  Regulation  No  (EC)  2309/93  of  22 
July 1993, as amended. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr. E. Abadie 
Co-Rapporteur:  Dr. D. Jefferys (until March 2000) 
Dr. F. Rotblat (from March 2000) 
Scientific Advice 
The Applicant did not seek Scientific Advice from the CPMP.  
Licensing status 
The  product  was  not  approved  in  any  country  at  the  time  of  the  submission  of  the  application.  The 
product has subsequently been approved in the USA on 29 December 1999. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 17 December 1999. 
The  Rapporteur's  initial  assessment  report  was  circulated  to  all  CPMP  Members  on  24 
February 2000.  The  Co-Rapporteur's  initial  assessment  report  was  circulated  to  all  CPMP 
Members on 3 March 2000. 
During  the  meeting  on  11-13  April  2000  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
Applicant on 13 April 2000. 
The Applicant submitted the responses to the consolidated List of Questions on 10 July 2000.  
The Rapporteur circulated the Joint Response Assessment Report on the Applicant’s responses 
to the List of Questions to all CPMP Members on 28 August 2000. 
The CPMP, during its September 2000 plenary meeting, adopted a list of outstanding issues to 
be addressed by the Applicant in writing. The final list was forwarded to the Applicant on 26 
September 2000. 
The Applicant submitted the responses to the outstanding list of issues on 5 October 2000. 
The Rapporteur circulated the Joint Response Assessment Report on the Applicant’s responses 
to the list of outstanding issues to all CPMP Members on 20 October 2000. 
The  CPMP,  in  the  light  of  the  overall  data  submitted  and  the  scientific  discussion  within  the 
Committee issued a positive opinion for granting a Marketing Authorisation to Targretin on 16 
November 2000. 
    1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
